中国创新药对外授权年交易额突破千亿美元，4年增长近10倍

Core Insights - In 2025, Chinese biopharmaceutical companies achieved a record high in out-licensing deals, surpassing $137.7 billion, nearly a tenfold increase from 2021, with 186 transactions [3] Group 1: Market Trends - Major global pharmaceutical companies, including Novartis, AstraZeneca, and GSK, signed significant agreements with Chinese firms last year [4] - The total value of these licensing deals is expected to double in the next 18 to 24 months, as global companies focus on finding next-generation innovative drug pipelines in China [4] - Nearly 40 out-licensing transactions have occurred this year, with average deal sizes significantly higher than last year [4] Group 2: Notable Transactions - On February 8, Innovent Biologics entered a strategic partnership with Eli Lilly, securing a total payment of $8.85 billion, including an upfront payment of $350 million and milestone payments of $8.5 billion [5] - Madrigal Pharmaceuticals announced a licensing agreement with Suzhou Ribo Biopharma for an experimental liver disease project, with a potential deal size of $4.4 billion [5] - AstraZeneca reached a collaboration agreement with China’s CSPC Pharmaceutical Group, potentially valued at $18.5 billion, to develop a next-generation GLP-1 weight loss therapy [5] Group 3: Industry Analysis - Macquarie Capital predicts that oncology drugs will continue to attract global pharmaceutical interest, highlighting China's strong capabilities in chemical drug development despite a gap in biological fields compared to the U.S. [6] - Multinational companies view China as a crucial part of their global R&D infrastructure, especially as they face patent cliffs and seek to reduce costs [6] - Vision Lifesciences' report indicates that China leads globally in specific molecular types, with Chinese companies accounting for nearly 90% of global out-licensing transactions for antibody-drug conjugates (ADCs) [6]